CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...

CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

I am delighted to serve as guest editor for the recently published CNS Drugs supplement, focused on key clinical issues for people with narcolepsy and their clinicians with a particular emphasis on ...

Following a one-day trip by a delegation of City Council members led by Mayor Karen Bass to Sacramento, state lawmakers ...

The driver of a semi-truck charged in the fatal 18-vehicle crash on I-35may have been under the influence of central nervous ...

Marathon running causes a temporary decline in brain myelin content, but levels return to normal within two months. This ...

The significant drop in CNS Pharmaceuticals’ stock price reflects investor concerns over the commercial viability of Berubicin following these trial results. The company’s next steps will likely be ...

The College of Natural Sciences Common Scholarship Application for current and continuing CNS students is now available through the Longhorn Awards & Student Scholarship Opportunities (LASSO) portal.

LG CNS has signed a memorandum of understanding (MOU) with the Silicon Valley-based artificial intelligence (AI) firm Weights ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma ...